Knowledge base
1,268 claims across 14 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,268ai alignment 325internet finance 262health 207space development 171entertainment 130grand strategy 101energy 23mechanisms 18collective intelligence 14manufacturing 5robotics 5critical systems 3unknown 3teleological economics 1
CVD mortality stagnation drives US life expectancy plateau 3-11x more than drug deaths inverting the dominant opioid crisis narrative
NCI researchers quantified the contribution of different mortality causes to US life expectancy stagnation between 2010 and 2017. CVD stagnation held back life expectancy at age 25 by 1.14 years in both women and men. Rising drug-related deaths had a much smaller effect: 0.1 years in women and 0.4 y
CVD mortality stagnation after 2010 reversed a decade of Black-White life expectancy convergence because structural cardiovascular improvements drove racial health equity gains more than social interventions
Between 2000-2009, CVD mortality declined faster for Black Americans than White Americans, narrowing the Black-White life expectancy gap by 1.39 years for women and 1.44 years for men. After 2010, this convergence stopped. Counterfactual analysis shows that if pre-2010 CVD trends had continued throu
EU Commission's December 2025 medical AI deregulation proposal removes default high-risk AI requirements shifting burden from requiring safety demonstration to allowing commercial deployment without mandated oversight
The European Commission's December 2025 proposal amends the AI Act so that AI medical devices remain within scope but are no longer subject to high-risk AI system requirements by default. The Commission retained only the power to adopt delegated or implementing acts to reinstate those requirements—n
FDA transparency requirements treat clinician ability to understand AI logic as sufficient oversight but automation bias research shows trained physicians defer to flawed AI even when they can understand its reasoning
The FDA's 2026 CDS Guidance places greater emphasis on transparency regarding data inputs, underlying logic, and how recommendations are generated. FDA explicitly noted concern about 'how HCPs interpret CDS outputs'—acknowledging automation bias exists—but treats transparency as the solution. The gu
Food insecurity creates a bidirectional reinforcing loop with cardiovascular disease where disease drives dietary insufficiency through medical costs and dietary insufficiency drives disease through ultra-processed food reliance
Food insecurity and cardiovascular disease form a bidirectional reinforcing loop through two distinct mechanisms. In the CVD→food insecurity direction, medical costs drain household food budgets, forcing dietary compromises. In the food insecurity→CVD direction, budget constraints drive consumption
Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver
Hypertensive disease age-adjusted mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023. Since 2022, hypertension has become the #1 contributing cardiovascular cause of death in the US, surpassing ischemic heart disease. This represents a fundamental epidemiological shift: the primary dr
Indian generic semaglutide exports enabled by evergreening rejection create a global access pathway before US patent expiry
The Delhi High Court division bench rejected Novo Nordisk's attempt to block Dr. Reddy's from exporting semaglutide, specifically citing concerns about 'evergreening and double patenting strategies.' This ruling is structurally significant because it removes the legal risk Indian manufacturers faced
LLM anchoring bias causes clinical AI to reinforce physician initial assessments rather than challenge them because the physician's plan becomes the anchor that shapes all subsequent AI reasoning
The GPT-4 anchoring study finding that 'incorrect initial diagnoses consistently influenced later reasoning' provides a cognitive architecture explanation for the clinical AI reinforcement pattern observed in OpenEvidence adoption. When a physician presents a question with a built-in assumption or i
LLM clinical recommendations exhibit systematic sociodemographic bias across all model architectures because training data encodes historical healthcare inequities
A Nature Medicine study evaluated 9 LLMs (both proprietary and open-source) using 1,000 emergency department cases presented in 32 sociodemographic variations while holding all clinical details constant. Across 1.7 million model-generated outputs, systematic bias appeared universally: Black, unhouse
LLM-generated nursing care plans exhibit dual-pathway sociodemographic bias affecting both plan content and expert-rated clinical quality
A cross-sectional simulation study published in JMIR (2025) generated 9,600 nursing care plans using GPT across 96 sociodemographic identity combinations and found systematic bias operating through two distinct pathways. First, the thematic content of care plans varied by patient demographics—what t
LLMs amplify rather than merely replicate human cognitive biases because sequential processing creates stronger anchoring effects and lack of clinical experience eliminates contextual resistance
The npj Digital Medicine 2025 paper documents that LLMs exhibit the same cognitive biases that cause human clinical errors—anchoring, framing, and confirmation bias—but with potentially greater severity. In GPT-4 studies, incorrect initial diagnoses 'consistently influenced later reasoning' until a
Medicaid work requirements cause coverage loss through procedural churn not employment screening because 5.3 million projected uninsured exceeds the population of able-bodied unemployed adults
The CBO projects 5.3 million Americans will lose Medicaid coverage by 2034 due to work requirements — the single largest driver among all OBBBA provisions. This number is structurally revealing: it exceeds the population of able-bodied unemployed Medicaid adults, meaning the coverage loss cannot be
Medical benchmark performance does not predict clinical safety as USMLE scores correlate only 0.61 with harm rates
The NOHARM study found that safety performance (measured as severe harm rate across 100 real clinical cases) correlated only moderately with existing AI and medical benchmarks at r = 0.61-0.64. This means that a model's USMLE score or performance on other medical knowledge tests explains only 37-41%
Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
The distinction between stagnation and reversal is critical for understanding the severity of the post-2010 health crisis. While old-age CVD mortality (ages 65-84) continued declining but at a much slower pace, many states experienced outright increases in midlife CVD mortality (ages 40-64) during 2
Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption
The Mount Sinai paper frames multi-agent clinical AI as an EFFICIENCY AND SCALABILITY architecture (65x compute reduction), while NOHARM's January 2026 study showed the same architectural approach reduces clinical harm by 8% compared to solo models. The Mount Sinai paper does not cite NOHARM's harm
Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload
Mount Sinai's peer-reviewed study distributed healthcare AI tasks (patient information retrieval, clinical data extraction, medication dose checking) among specialized agents versus a single all-purpose agent. The multi-agent architecture reduced computational demands by up to 65x while maintaining
Provider tax freeze blocks state CHW expansion by eliminating the funding mechanism not the program because provider taxes fund 17 percent of state Medicaid share and CHW SPAs require state match
The OBBBA provider tax freeze creates a structural contradiction for CHW expansion: 20 states now have federal SPA approval for CHW reimbursement (as of March 2025), but provider taxes fund 17%+ of state Medicaid share nationally (30%+ in Michigan, NH, Ohio). States are prohibited from establishing
Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
The European Commission's December 2025 proposal to 'simplify' medical device regulation removed default high-risk AI system requirements from the AI Act for medical devices, while the FDA expanded enforcement discretion for clinical decision support software in January 2026. This simultaneous dereg
Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
The simultaneous release of the EU Commission's proposal to ease AI Act requirements for medical devices and WHO's explicit warning of 'heightened patient risks due to regulatory vacuum' documents a regulator-vs.-regulator split at the highest institutional level. The Commission proposed postponing
Tailored digital health interventions achieve clinically significant systolic BP reductions at 12 months in US populations experiencing health disparities, but the effect is conditional on design specificity for these populations rather than generic deployment
A systematic review and meta-analysis of 28 studies covering 8,257 patients found that digital health interventions produced clinically significant reductions in systolic blood pressure at both 6 and 12 months in populations experiencing health disparities (racial/ethnic minorities, low-income adult
Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036
Tirzepatide's patent protection extends significantly beyond semaglutide through a deliberate thicket strategy: primary compound patent expires 2036, with formulation and delivery device patents extending to approximately December 30, 2041. This contrasts sharply with semaglutide, which expired in I
All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
The UK House of Lords Science and Technology Committee launched its NHS AI inquiry on March 10, 2026, with explicit framing as an adoption failure investigation: 'Why does the NHS adoption of the UK's cutting-edge life sciences innovations often fail, and what could be done to fix it?' The inquiry e
Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate
The REGARDS cohort tracked 5,957 adults free from hypertension at baseline for 9.3 years (2003-2016). Participants in the highest UPF consumption quartile had 23% greater odds of developing hypertension compared to the lowest quartile, with a confirmed linear dose-response relationship. 36% of the i
Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control
The REGARDS cohort establishes that UPF consumption drives incident hypertension through chronic elevation of inflammatory biomarkers (CRP, IL-6) that cause endothelial dysfunction. In food-insecure households, this creates a circular mechanism: (1) limited access to affordable non-UPF foods forces
US CVD mortality is bifurcating with ischemic heart disease declining while heart failure and hypertensive disease reach all-time highs revealing that aggregate improvement masks structural deterioration in cardiometabolic health
The AHA 2026 report reveals a critical bifurcation in CVD mortality trends. While overall age-adjusted CVD mortality declined 33.5% from 1999 to 2023 (350.8 to 218.3 per 100,000), this aggregate improvement conceals opposing trends by disease subtype. Ischemic heart disease and cerebrovascular disea
Page 4 of 9